Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the global Anticoagulants market. In addition, complete analysis of changes on the global Anticoagulants market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. During COVID-19 pandemic, global anticoagulants market was significantly affected due to supply chain distribution, which has certainly affected the supply of anticoagulants to essential consumers and also affected the market growth to a major extent. However, post COVID-19, with loosening of restrictions, the market is expected to exhibit new growth opportunities and is expected to have an emerging demand in the upcoming years.
The global anticoagulants market is driven by the key factors such as the rise in the population of elderly people and increasing prevalence of obese population are most likely to increase the demand for the growth of anticoagulants market over the forecast period. The rise in geriatric population has propelled an increase in various chronic diseases and disorders among the geriatric population. Due to the increasing incidence of ischemic heart disease and venous thromboembolism (VTE), cardiovascular diseases, increasing acceptance of Novel Oral Anticoagulants (NOACs) and awareness of NOACs, these factors are expected to drive the growth in the anticoagulant market during the period.
The market is expected to have growing new growth opportunities with rise in investment in research and development activities by the manufacturers to develop innovative, effective and safer anticoagulants. The advancement of oral anticoagulants, combinations containing pharmaceutical ingredients, with the support of new oral anticoagulants technology can foster great growth opportunities in the anticoagulants market.
The global anticoagulants market is expected to have market restraints like higher cost of novel anticoagulants and ambiguity of related risk of after effects and complexities along with the usage of oral anticoagulants. These are the concerning elements which is expected to restrain the market growth during the forecast period.
The major growth challenge for the market is high cost of antidotes for novel anticoagulants. Likewise, stringent regulation and quality standard for anticoagulants is expected to be major growth challenge for the market.
The report provides in-depth analysis of global anticoagulants market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various Anticoagulants in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
The global anticoagulants market comprises of different market segments like drug class, route of administration, application and geography.
Based on drug class, the global anticoagulants market is segmented into Novel Oral Anticoagulants (NOACs), heparin and low molecular weight heparin (LMWH), vitamin K antagonist, and others. Novel Oral Anticoagulants (NOACs includes key sub-segments of Eliquis, Bevyxxa, Xarelto, Savaysa & lixiana and Pradaxa. Currently, NOAC segment is a major revenue-generating segment in the anticoagulants market and is expected to dominate over the forecast period owing to the growing adoption of NOACs in developing countries and increasing usage of NOACs compared to warfarin. Currently, NOAC drugs such as Rivaroxaban, Betrixaban, Apixaban, Edoxaban, and Dabigatran are available in the market. Additionally, NOACs offer several advantages over warfarin, such as: B. rapid onset of action, fewer drug and food interactions, predictable pharmacokinetic effect, shorter half-life, and no dietary restrictions. These have further supported the growth of the market.
Based on route of administration, the global anticoagulants market is segmented into oral anticoagulants and injectable anticoagulants. Oral anticoagulants route of administration is anticipated to lead in the global anticoagulants market from 2022 to 2028. The growth is driven by various factors like the ease in administration along with ease in availability of novel oral anticoagulants. Also, due to increased use of injectable anticoagulants in various surgical procedures, injectable anticoagulants is expected to have growing demand in market during the estimated time period.
The global anticoagulants market finds its major application in atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE) among others. Due to the increasing incidence of ischemic heart disease and venous thromboembolism (VTE), cardiovascular diseases, there is a general increase in demand for various anticoagulants. Currently, the atrial fibrillation and heart attacks segment is a major contributor to revenue and is expected to dominate over the forecast period, thanks to its large target audience and increased use of anticoagulants in the treatment of these conditions. However, deep vein thrombosis (DVT) is expected to experience the fastest growth in the market, due to the higher prevalence of DVT and technological advances in DVT diagnosis.
The global anticoagulants market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North America is anticipated to lead in the Anticoagulants market during the forecast period (2022-2028). North America dominates the anticoagulant market due to the increasing prevalence of cardiovascular diseases, chronic disease and venous thromboembolism. Chronic diseases, such as heart disease, cancer and diabetes, are the leading factors causing cardiac issues. The rise in rates of cardiovascular disease and the increase in surgical procedures is driving the market growth in this region. European countries have shown tremendous growth due to the increase in the geriatric population in the market.
The competitive landscape analysis of Anticoagulants market is majorly focused on expanding the global growth of anticoagulants with new product launches, partnership/ agreement and merger & acquisitions which has boosted the market growth at highest pace. Besides, presence of wide range of manufacturers operating in the market offers range of anticoagulant drugs in different application to fulfill the required demand has further contributed healthy growth in the market.
The key players studied in market are Aspen Holdings, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Abbott Laboratories, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Daiichi Sankyo Company, Pfizer, Inc., Sanofi S.A, Eli Lilly and Company, Medicure, Portola Pharmaceuticals Inc., Novartis AG, and Eisai Co., Ltd. among others.
October 2019: The Food and Drug administration (FDA) had granted approval for the indications of the additional disease of the prevention of venous thromboembolism (VTE) in the hospitals to thoroughly treat the patients who are at risk of thromboembolic complication.
February 2019: Novartis AG and Blackstone’s life science had launched Anthos Therapeutics for the development of the cardiovascular drugs and anticoagulants.
Anticoagulants are drugs that help block blood clots. A blood clot is a seal formed by the blood to prevent wounds from bleeding. Anticoagulants are chemicals that block or prevent blood clotting and slow blood clotting time. The anticoagulants are also called as blood thinners. They are given to patients who are at high risk of getting blood clots, to slow down the possibility of developing serious conditions, such as strokes and heart attacks. If a blood clot prevents blood from flowing through a vessel, the affected body part becomes devoid of oxygen and will no longer function properly. Blood thinners produce the effects by breaking the fusion or function of various clotting factors present in the blood. Along with growing elderly population, there is a huge increase in incidences of various cardiovascular and other diseases. Also, there is a surge in demand for novel therapeutics with respect to anticoagulants. This factor is also expected to fuel the market growth within the forecast period. The global anticoagulants market comprises of different market segments like drug class, route of administration, application and geography. By drug class, the anticoagulants includes key segments of novel oral anticoagulants (NOAC), heparin & low molecular weight heparin (LMWH), vitamin k antagonist and others.
The novel oral anticoagulants (NOAC) segment is likely to have growing demand in the market. The market is significantly studied for key route of administrations like oral anticoagulants and injectable anticoagulants. Oral anticoagulants is anticipated to lead in the market from 2022 to 2028. The market finds its major applications in atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE) among others.
The atrial fibrillation & heart attack application has register major market is expected to maintain its dominance over the estimated time period. The global anticoagulants market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW).
1) Who are leading players in the global Anticoagulants market?
Ans: The key players studied in market are Aspen Holdings, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Abbott Laboratories, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Daiichi Sankyo Company, Pfizer, Inc., Sanofi S.A, Eli Lilly and Company, Medicure, Portola Pharmaceuticals Inc., Novartis AG, and Eisai Co., Ltd. among others.
2) Which is the leading application segment for Anticoagulants market?
Ans: The atrial fibrillation & heart attack application has accounted the major market share, and is expected to witness the growth at highest pace during the forecast period.
3) Which region is gaining majority of market share during the forecast period (2022-2028)?
Ans: North is expected to gain major market share during the forecast period (2022-2028).
